FDA Clearance Tracker · P030017-S396
WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 9, 2026
Approved
Time to decision
90 days
Received Jun 11, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P030017-S396
- Device name
- WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Jun 11, 2026
- Decided
- Sep 9, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P030017
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
the removal of the precaution statement related to subperception therapy in the Information for Prescribers and Information for Patients user manuals for the WaveWriter Alpha, WaveWriter Alpha Prime, Celestia, and Celestia Prime Spinal Cord Stimulation (SCS) Systems.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.